Search clinical trials for: CHOP chidamide tislelizumab

Total 1097 results

Tianjin Medical University Cancer Institute and...

Recruiting

Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer

Head and Neck Cancer

China
Quanli Gao

Not yet recruiting

L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma

Malignant Melanoma
Peking Union Medical College Hospital
Harbin Medical University; The First Affiliated Hospital of Xiamen University

Recruiting

Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm

Neuroendocrine Tumors | Neuroendocrine Carcinoma | Neuroendocrine Neoplasm | Neuroendocrine Tumor Grade 3

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer

Breast Cancer | Chemotherapy Effect

China
Chinese PLA General Hospital

Recruiting

Ruxolitinib and Chidamide for Acute T Cell Lymphoblast Leukemia/ Lymphoblastic Lymphoma

Peripheral Blood Stem Cell Transplantation

China
Amgen

Completed

Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy

Cancer | Anemia | Non-Myeloid Malignancies
Northwell Health
Pharmacyclics LLC.

Terminated

Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients

Richter Syndrome

United States
BeiGene

Recruiting

Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

China, Georgia, Moldova, Republic of
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Recruiting

Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

Solid Tumor | Classic Hodgkin Lymphoma

China
RenJi Hospital

Recruiting

Combination of RC48 and Tislelizumab for Renal Preservation in High-risk UTUC Patients

Upper Urinary Tract Urothelial Carcinoma | Kidney Preservation | HER-2 ADC | PD-1antibody

China
The First Affiliated Hospital of Zhengzhou University

Active, not recruiting

Tislelizumab in Addition to BACE in Patients With NSCLC

NSCLC

China
Great Novel Therapeutics Biotech & Medicals Corporation

Recruiting

Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma (HCC)

Taiwan
Sun Yat-sen University

Recruiting

Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL

Safety and Efficacy

China
Sun Yat-sen University

Not yet recruiting

Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL

Angioimmunoblastic T-cell Lymphoma

China
Huiqiang Huang

Completed

Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL

Safety and Efficacy

China
Guangzhou 8th People's Hospital
Sun Yat-sen University

Completed

Effect of Chidamide Combined With CAT-T or TCR-T Cell Therapy on HIV-1 Latent Reservoir

HIV/AIDS

China
West China Hospital

Not yet recruiting

SOX Combined With Tislelizumab and LDRT for Neoadjuvant Treatment of Locally Advanced Gastric Cancer

Gastric Cancer
First Affiliated Hospital of Guangxi Medical University

Recruiting

The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer

Rectal Cancer | Rectal Cancer Stage II | Rectal Cancer Stage III

China
Hutchmed
BeiGene

Active, not recruiting

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Soft Tissue Sarcoma | Small Cell Lung Cancer | Gastric Cancer | Colorectal Cancer | Neuroendocrine Tumors | Metastatic Solid Tumor | Anaplastic Thyroid Cancer

United States
Peking University Cancer Hospital & Institute

Recruiting

Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC

Unresectable Hepatocellular Carcinoma | Oligometastatic Disease

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer (NEXUS-2)

Esophagus Cancer

China
Novartis Pharmaceuticals

Recruiting

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-01)

Carcinoma, Non-Small-Cell Lung | Lung Cancer | Neoplasms, Lung | Pulmonary Neoplasms | Neoplasms, Pulmonary | Pulmonary Cancer | Cancer of Lung | Cancer of the Lung | KRAS G12C Mutant Solid Tumors | Carcinoma, Colorectal

United States, Japan, Australia, Germany, Italy, Spain, Canada, Denmark, Korea, Republic of, Taiwan, Belgium, Hong Kong, China, France, Singapore, Netherlands
BeiGene

Active, not recruiting

Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Non Small Cell Lung Cancer | Advanced Solid Tumor | Head and Neck Squamous Cell Carcinoma (HNSCC) | Nasopharyngeal Carcinoma (NPC)

Canada, Australia, New Zealand, Korea, Republic of, United States, Malaysia, Thailand
Translational Research in Oncology
Bayer; Novartis

Withdrawn

Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers (REFIT-MSS)

Soft Tissue Sarcoma | Small Cell Lung Carcinoma | Colorectal Neoplasms | Anal Squamous Cell Carcinoma | Malignant Pleural Mesothelioma | Castrate Resistant Prostate Cancer | Gastroenteropancreatic Neuroendocrine Neoplasm | Neuroendocrine Carcinoma of Prostate
The University of Hong Kong

Completed

A Cohort Study of Conversion From Aranesp® to NESP® for the Treatment of Anemia in Dialysis Patients

Anemia | End Stage Renal Failure on Dialysis

Hong Kong
BeiGene

Withdrawn

Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma

Hepatocellular Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

An Phase III Study, Multicenter，Randomized Controlled Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Bladder Cancer

China
Wuhan Union Hospital, China

Recruiting

The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression

Breast Cancer | Neoadjuvant Therapy

China
Second Affiliated Hospital of Nanchang University

Recruiting

Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pulmonary Pleomorphic Carcinoma

Immunotherapy | Tislelizumab | Pulmonary Pleomorphic Carcinoma

China
Huazhong University of Science and Technology

Active, not recruiting

Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC

Patients With Advanced Metastatic Colorectal Cancer

China
Haruhiko Fukuda
Ministry of Health, Labour and Welfare, Japan

Completed

Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)

Lymphoma, B-Cell

Japan
Daping Hospital and the Research Institute of Surgery...

Not yet recruiting

To Explore the Effect of Immune-induced Stereotactic Body Radiotherapy (SBRT) on Reversing Immunoresistance in Stage IIIc/IV Non-small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder)
West China Hospital

Recruiting

PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer

Thyroid Cancer

China
Guangxi Medical University

Not yet recruiting

Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation (PREVENT-2)

Recurrence | Hepatocellular Carcinoma | Immune Checkpoint Inhibitor

China
Akeso

Recruiting

AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

Advanced Squamous Non Small Cell Lung Cancer

China
Wai-Tong Chien
Castle Peak Hospital

Completed

The Potential Efficacy of the Chinese Health Improvement Profile- A Pilot Clustered Randomised Controlled Trial (CHIP)

Schizophrenia | Schizoaffective Disorder | Bipolar Affective Disorder | Cardiovascular Health | Severe Mental Illness
Fudan University

Completed

Chidamide Combined With Cisplatin in Head and Neck Adenoid Cystic Carcinoma (HNACC)

Cisplatin | Adenoid Cystic Carcinomas

China
First Affiliated Hospital Xi'an Jiaotong University

Active, not recruiting

Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma (TINES) (TINES)

Esophageal Squamous Cell Carcinoma

China
Tang-Du Hospital
Chipscreen Biosciences, Ltd.

Completed

Chidamide in Combination With Antiretroviral Therapy for Eradication of the Latent HIV-1 Reservoir (CHARTER)

Chronic HIV Infections

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Evaluation of The Efficacy And Safety of PD-1 + IL-2 Combined With Capox Treatment After Loop Colostomy Surgery in Left-sided Colorectal Cancer Patients Complicating Acute Obstruction

Left-sided Colorectal Cancer Complicating Acute Obstruction
Daping Hospital and the Research Institute of Surgery...

Recruiting

Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors

Gastric Cancer | Rectal Cancer | Chemotherapy Effect | Radiotherapy | Immunotherapy

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients

Diffuse, Large B-Cell, Lymphoma

China
Winston Laboratories

Completed

Civamide in OA of the Knee(s)

Osteoarthritis, Knee

United States
Sinocelltech Ltd.

Unknown

A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients

Diffuse Large B Cell Lymphoma

China
Sun Yat-sen University
Hutchmed; BeiGene

Not yet recruiting

Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer

Metastatic Colorectal Cancer | mCRC

China
Fudan University

Recruiting

The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)

Metastatic Colorectal Cancer

China
Peking University Cancer Hospital & Institute

Not yet recruiting

Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer (PKUCH-R09)

Rectal Cancer

China
Immix Biopharma, Inc.
Novartis; BeiGene

Recruiting

Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors (IMMINENT-01)

Advanced Solid Tumor

Brazil
Massachusetts General Hospital
M.D. Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Dana-Farber...

Completed

Detecting EGFR T790M Mutations From Circulating Tumor Cells

Non Small Cell Lung Cancer

United States
Shandong Cancer Hospital and Institute
The First Affiliated Hospital of Nanchang University

Recruiting

A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma

The First Affiliated Hospital of Nanchang University

China

Search clinical trials for: CHOP chidamide tislelizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations